Old and new tools to assess dyspnea in the hospitalized patient

Current Heart Failure Reports

Volumn 10, Issue 3, 2013, Pages 204-211

  Kjellström, Barbro ^a,c   Van Der Wal, Martje H L ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Assessment tools; Breathlessness; Dyspnea; Heart failure; Scales

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN;

ARTICLE; BREATHING; BREATHING RATE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL PRACTICE; DEFIBRILLATOR; DYSPNEA; ELECTROCARDIOGRAM; EMPLOYMENT; HEART FAILURE; HEART SOUND; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LUNG CONGESTION; MEDICAL RESEARCH; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; SOCIAL BEHAVIOR; VISUAL ANALOG SCALE;

DYSPNEA; HEART FAILURE; HEMATOLOGIC TESTS; HOSPITALIZATION; HUMANS; PHYSICAL EXAMINATION; SEVERITY OF ILLNESS INDEX;

EID: 84881476926     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-013-0141-0     Document Type: Article

References (66)

1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803-69.
2. Jeon YH, Kraus SG, Jowsey T, Glasgow NJ. The experience of living with chronic heart failure: a narrative review of qualitative studies. BMC Health Serv Res. 2010;10:77-86.
3. Moser DK, Frazier SK, Worrall-Carter L, et al. Symptom variability, not severity, predicts rehospitalization and mortality in patients with heart failure. Eur J Cardiovasc Nurs. 2011;10:124-9.
4. Opasich C, Gualco A, De Feo S, et al. Physical and emotional symptom burden of patients with end-stage heart failure: what to measure, how and why. J Cardiovasc Med. 2008;9:1104-8.
5. Nordgren L, Sfrensen S. Symptoms experienced in the last six months of life in patients with end-stage heart failure. Scand J Caring Sci. 2003;2:213-7.
6. Metra M, Teerlink JR, Felker GM, et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail. 2010;12:1130-9.
7. Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. Eur J Cardiovasc Nurs. 2005;4:198-206.
8. Kato M, Stevenson LW, Palardy M, et al. The worst symptom as defined by patients during heart failure hospitalization: implications for response to therapy. J Card Fail. 2012;18:524-33.
9. • Ekman I, Granger B, Swedberg K, Stenlund H, Boman K. Measuring shortness of breath in heart failure (SOB-HF): development and validation of a new dyspnoea assessment tool. Eur J Heart Fail. 2011;13:838-45. This paper shows, in a very well described manner, the complexity of developing a new symptom assessment tool.
10. Patel H, Shafazand M, Schaufelberger M, Ekman I. Reasons for seeking acute care in chronic heart failure. Eur J Heart Fail. 2007;9:702-8.
11. Parshall MB, Schwartzstein RM, Adams L, et al. American Thoracic Society Committee on Dyspnea. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185:435-52.
12. Agostoni P, Cattadori G, Bussotti M, Apostolo A. Cardiopulmonary interaction in heart failure. Pulm Pharmacol Ther. 2007;20:130-4.
13. Bernardi L, Gabutti A, Porta C, Spicuzza L. Slow breathing reduces chemoreflex response to hypoxia and hypercapnia, and increases baroreflex sensitivity. J Hypertens. 2001;19:2221-9.
14. Harrington D, Coats AJS. Skeletal muscle abnormalities and evidence for their role in symptom generation in chronic heart failure. Eur Heart J. 1997;18:1865-72.
15. • Wahls SA. Causes and evaluation of chronic dyspnea. Am Fam Physician. 2012;86:173-82. This is a well-written review paper about the clinical assessment of dyspnea in general practice.
16. Kataoka H, Madias JE. Changes in the amplitude of electrocardiogram QRS complexes during follow-up of heart failure patients. J Electrocardiol. 2011;44:394.e1-9.
17. Madias JE. Why recording of an electrocardiogram should be required in every inpatient and outpatient encounter of patients with heart failure. Pacing Clin Electrophysiol. 2011;34:963-7.
18. von Haehling S, van Veldhuisen DJ, Roughton M, et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: Results from the SENIORS study. Eur J Heart Fail. 2011;13:656-63.
19. Maeder MT, Khammy O, dos Remedios C, Kaye DM. Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol. 2011;58:474-80.
20. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58:1241-51.
21. Mastandrea P. The diagnostic utility of brain natriuretic peptide in heart failure patients presenting with acute dyspnea: a meta-analysis. Clin Chem Lab Med. 2012;8:1-11. doi: 10.1515/cclm-2012-0503.
22. • Kelder JC, Cowie MR, McDonagh TA, et al. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart. 2011;97:959-63. This meta-analysis quantifies the added diagnostic value of BNP for the diagnosis of heart failure in a population relevant to general practitioner, through individual patient data.
23. Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag. 2010;6:411-8.
24. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55:2062-76.
25. Worster A, Balion CM, Hill SA, et al. Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: a systematic review. Clin Biochem. 2008;41:250-9.
26. Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic Peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One. 2013;8:e58287.
27. Saremi A, Gopal D, Maisel AS. Brain natriuretic peptide-guided therapy in the inpatient management of decompensated heart failure. Expert Rev Cardiovasc Ther. 2012;10:191-203.
28. Tan TC, Sindone AP, Denniss AR. Cardiac electronic implantable devices in the treatment of heart failure. Heart Lung Circ. 2012;21:338-51.
29. Whellan DJ, Adams S, Bowerman L. Review of advanced heart failure device diagnostics examined in clinical trials and the potential benefit from monitoring capabilities. Prog Cardiovasc Dis. 2011;54:107-14.
30. Sarkar S, Koehler J, Crossley GH, et al. Burden of atrial fibrillation and poor rate control detected by continuous monitoring via implanted devices identifies when a patient is at risk for heart failure hospitalization. Am Heart J. 2012;164:616-24.
31. Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from partners hf (program to access and review trending information and evaluate correlation to symptoms in patients with heart failure) study. J Am Coll Cardiol. 2010;55:1803-10.
32. Cowie MR, Sarkar S, Koehler J et al. Development and validation of an integrated diagnostic algorithm derived from parameters monitored in implantable devices for identifying patients at risk for heart failure hospitalization in an ambulatory setting. Eur Heart J. 2013. doi: 10.1093/eurheartj/eht083.
33. Conraads VM, Tavazzi L, Santini M, et al. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. Eur Heart J. 2011;32:2266-73.
34. van Veldhuisen DJ, Braunschweig F, Conraads V, et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation. 2011;124:1719-26.
35. Herigstad M, Hayen A, Wiech K, et al. Dyspnoea and the brain. Respir Med. 2011;105:809-17.
36. Evans KC, Banzett RB, Adams L, et al. BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol. 2002;88:1500-11.
37. Banzett RB, Mossavi S. Dyspnea and pain: similarities and contrasts between two very unpleasant sensations. APS Bull. 2001;11:1-8.
38. Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis. 1987;40:593-603.
39. Teerlink JR, Cotter G, Davison BA, et al. RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29-39.
40. Mebazaa A, Pang PS, Tavares M, et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J. 2010;31:832-41.
41. Allen LA, Metra M, Milo-Cotter O, et al. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF]. J Card Fail. 2008;14:777-84.
42. Borg G. A category scale with ratio properties for intermodal and interindividual comparisons. In: Geissler HG, Petzold P, editors. Psychophysical judgement and the process of perception. Berlin: VEB Deutscher Verlag der Wissenschaften; 1982.
43. Nomura F, Kurobe N, Mori Y, et al. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: carperitide effects observed through monitoring dyspnea in Acute Decompensated Heart Failure study. Circ J. 2008;72:1777-86.
44. Fletcher CM, Elmes PC, Fairbairn MB, et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J. 1959;2:257-66.
45. Fletcher CM. The clinical diagnosis of pulmonary emphysema-an experimental study. Proc R Soc Med. 1952;45:577-84.
46. Torchio R, Gulotta C, Greco-Lucchina P, et al. Closing capacity and gas exchange in chronic heart failure. Chest. 2006;129:1330-6.
47. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85:751-8.
48. Feinstein AR, Fisher MB, Pigeon JG. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol. 1989;64:50-5.
49. Heo S, Doering LV, Widener J, Moser DK. Predictors and effect of physical symptom status on health-related quality of life in patients with heart failure. Am J Crit Care. 2008 Mar;17(2):124-32.
50. Corvera-Tindel T, Doering LV, Woo MA, Khan S, Dracup K. Effects of a home walking exercise program on functional status and symptoms in heart failure. Am Heart J. 2004;147:339-46.
51. Riegger GA, Bouzo H, Petr P, Münz J, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation. 1999;100:2224-30.
52. Lang RM, Elkayam U, Yellen LG, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol. 1997;4:983-91.
53. Scano G, Stendardi L, Grazzini M. Understanding dyspnoea by its language. Eur Respir J. 2005;25:380-5.
54. Elliott MW, Adams L, Cockcroft A, et al. The language of breathlessness. Use of verbal descriptors by patients with cardiopulmonary disease. Am Rev Respir Dis. 1991;144:826-32.
55. Simon PM, Schwartzstein RM, Weiss JW, et al. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis. 1990;142:1009-14.
56. Parshall MB, Carle AC, Ice U, Taylor R, Powers J. Validation of a three-factor measurement model of dyspnea in hospitalized adults with heart failure. Heart Lung. 2012;41:44-56.
57. Parshall MB, Welsh JD, Brockopp DY, et al. Reliability and validity of dyspnea sensory quality descriptors in heart failure patients treated in an emergency department. Heart Lung. 2001;30:57-65.
58. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-7.
59. • Oxberry SG, Bland JM, Clark AL, Cleland JG, Johnson MJ. Minimally clinically important difference in chronic breathlessness: every little helps. Am Heart J. 2012;164:229-35. Few studies are made to appreciate a clinically important change in a symptom score. This paper describes, in detail, one method for this type of evaluation.
60. Ander DS, Aisiku IP, Ratcliff JJ, Todd KH, Gotsch K. Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful? Congest Heart Fail. 2004;10:188-91.
61. Likert, R. A Technique for the Measurement of Attitudes, Archives of Psychology, No.140:1-55, 1932
62. Bowling A. Research Methods in Health. Buckingham: Open University Press; 1997.
63. Burns N, Grove SK. The Practice of Nursing Research Conduct, Critique, & Utilization. Philadelphia: W.B. Saunders and Co.; 1997.
64. • Meek PM, Banzett R, Parshall MB, et al. Reliability and validity of the multidimensional dyspnea profile. Chest. 2012;141:1546-53. This paper describes in a well-documented way the method to develop a new symptom assessment tool.
65. • Parshall MB, Meek PM, Sklar D, Alcock J, Bittner P. Test-retest reliability of multidimensional dyspnea profile recall ratings in the emergency department: a prospective, longitudinal study. BMC Emerg Med. 2012;12:6. In this paper the method to develop and assess a new symptom assessment tool is continued to the next level.
66. Banzett RB, Pedersen SH, Schwartzstein RM, Lansing RW. The affective dimension of laboratory dyspnea: air hunger is more unpleasant than work/effort. Am J Respir Crit Care Med. 2008;177:1384-90.